Ignite Creation Date:
2024-05-05 @ 4:51 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00321100
Status:
TERMINATED
Last Update Posted:
2022-01-12
First Post:
2006-05-01
Brief Title:
Combination of Cetuximab Capecitabine and Oxaliplatin With or Without Bevacizumab
Sponsor:
Fox Chase Cancer Center
Organization:
Fox Chase Cancer Center
Organization Data
Organization:
Fox Chase Cancer Center
Class:
OTHER
Study ID:
FER-GI-002
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Fox Chase Cancer Center
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None